Phase II funding will be used for pre-clinical assessment of regenerative cartilage therapy Follows Phase I SBRI funding, announced in April 2019 Cambridge, UK, 28 January 2020 Mogrify Ltd (Mogrify™), a UK company aiming to transform the Read More
Tags :SBRI
Oxford Drug Design (ODD) wins major funding awards from CARB-X, the UK Department of Health and Social Care (DHSC) and an equity investment led by o2h Ventures totalling over £8m to develop new antibiotics Read More
Healthcare to advance regenerative cartilage therapy to the clinic Chondrogenix will use Mogrify’s data-driven conversion platform to generate a safe, efficient and scalable source of cartilage cells for the treatment of osteoarthritis Cambridge, UK, 1 Read More